Related Experiment Videos
Aprepitant--a novel NK1-receptor antagonist
1Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Expert Opinion on Pharmacotherapy
|December 4, 2003
Summary
Substance P antagonists, like aprepitant, offer a new way to manage chemotherapy-induced nausea and vomiting (CINV). This drug also shows potential for treating other conditions involving substance P.
Area of Science:
- Pharmacology
- Oncology
- Neuroscience
Background:
- Substance P antagonists represent a novel therapeutic class for managing emesis.
- Aprepitant is the first FDA-approved agent in this class for chemotherapy-induced nausea and vomiting (CINV).
- Substance P's involvement in pain, anxiety, depression, and inflammation suggests broad therapeutic potential for its antagonists.
Purpose of the Study:
- To provide an overview of aprepitant, a substance P antagonist.
- To review the pharmacokinetics, pharmacology, and clinical evidence for aprepitant in CINV.
- To briefly discuss potential alternative indications for aprepitant.
Main Methods:
- Review of existing literature on aprepitant.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Evaluation of clinical trial results for CINV prevention.
Main Results:
- Aprepitant is effective in preventing both acute and delayed CINV.
- Pharmacokinetic and pharmacology profiles support its use in CINV.
- Emerging evidence suggests potential applications beyond CINV.
Conclusions:
- Aprepitant is a significant advancement in managing CINV.
- The broad roles of substance P indicate a promising future for substance P antagonists in various medical fields.
- Further research is warranted to explore aprepitant's full therapeutic potential.